Safety and Tolerability of Dalcetrapib

Efficacy and safety data for dalcetrapib (RO4607381/JTT-705) are presented, following a report of increased mortality and cardiac events with another cholesteryl ester transfer protein inhibitor, torcetrapib, associated with off-target adverse effects (hypertension and the activation of the renin-an...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The American journal of cardiology 2009-07, Vol.104 (1), p.82-91
Hauptverfasser:	Stein, Evan A., MD, PhD, Stroes, Erik S.G., MD, PhD, Steiner, George, BA, MD, Buckley, Brendan M., DPhil, Capponi, Alessandro M., PhD, Burgess, Tracy, MSc, Niesor, Eric J., PhD, Kallend, David, MB BS Lon, Kastelein, John J.P., MD, PhD
Format:	Artikel
Sprache:	eng
Schlagworte:	Anticholesteremic Agents - adverse effects Anticholesteremic Agents - therapeutic use Biological and medical sciences Blood pressure Cardiology. Vascular system Cardiovascular Cardiovascular disease Cholesterol Cholesterol Ester Transfer Proteins - antagonists & inhibitors Clinical trials Coronary Artery Disease - drug therapy Double-Blind Method Dyslipidemias - drug therapy Female Humans Incidence Inhibitor drugs Male Medical sciences Middle Aged Placebo effect Quinolines - adverse effects Quinolines - therapeutic use Risk Assessment Risk Factors Safety Sulfhydryl Compounds - adverse effects Sulfhydryl Compounds - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!